Our in vitro services include over 500 validated and well-characterized cell lines for drug response screening and, as the only CRO service provider of HUB organoids
Explore our in vitro services
Our ex vivo services feature a 3D platform for evaluating monotherapy and combination drug responses in patient tumors with endogenous immune cell populations intact. The platform includes the option to use in co-culture with autologous immune cells and is suitable for many cancer types.
Explore our ex vivo services